Patent Incentive For Bioterrorism Research Offered In Lieberman Bill
Executive Summary
Pharmaceuticals approved for use as anti-bioterrorism agents would be eligible for full patent term restoration under legislation introduced by Sen. Joe Lieberman (D-Conn.) on Dec. 4
You may also be interested in...
Bioterror Patent Extensions Offered To Big Firms Under Revised Lieberman Bill
Large biotech firms producing counterterrorism measures could receive a two-year extension of a patent for another product under legislation introduced by Sen. Joseph Lieberman (D-Conn.)
Bioterror Patent Extensions Offered To Big Firms Under Revised Lieberman Bill
Large biotech firms producing counterterrorism measures could receive a two-year extension of a patent for another product under legislation introduced by Sen. Joseph Lieberman (D-Conn.)
Bioterrorism Product Research Tax Credit Expanded Under Lieberman Bill
Bioterrorism product research tax credits would be expanded to include companies with tax liability, such as larger biotech and pharma firms, under reworked legislation being developed by Sen. Joseph Lieberman (D-Conn.)